Cancer Stem Cell News Volume 3.14 | Apr 16 2014

CD58, a Novel Surface Marker, Promotes Self-Renewal of Tumor-Initiating Cells in Colorectal Cancer
Scientists found that CD58 and CD44 were upregulated using a cDNA GeneChip, and CD44^highCD58^high cancer cells, the common existence of which was demonstrated by flow cytometry in multiple colon cancer cell lines and primary specimens, exhibited enhanced self-renewal ability, epithelial-mesenchymal transition ability and tumorigenicity, both in vitro and in vivo. [Oncogene] Abstract

A New Mosaic Pattern in Glioma Vascularization: Exogenous Endothelial Progenitor Cells Integrating into the Vessels Containing Tumor-Derived Endothelial Cells
Scientists found a new mosaic pattern that exogenous endothelial progenitor cells (EPCs) integrated into the vessels containing the tumor-derived endothelial cells in C6 glioma rat model. Further, they evaluated the effect of these homing EPCs on C6 glioma cells transdifferentiation. [Oncotarget] Full Article

Culture Dimensionality Influences the Resistance of Glioblastoma Stem-Like Cells to Multikinase Inhibitors
Researchers studied the effects of substrate properties including elasticity, dimensionality and matrix composition on the response of glioblastoma stem-like cells to chemotherapeutic agents. [Mol Cancer Ther] Abstract

Pancreatic Cancer Stem-Like Cells Display Aggressive Behavior Mediated via Activation of FoxQ1
Researchers found that isolated triple-marker positive cells of human pancreatic cancer MiaPaCa-2 and L3.6pl cells behave as cancer stem-like cells (CSLCs). These CSLCs exhibit aggressive behavior such as increased cell growth, migration, clonogenicity, and self-renewal capacity. [J Biol Chem] Abstract | Full Article

Cobblestone-Area Forming Cells Derived from Patients with Mantle Cell Lymphoma Are Enriched for CD133⁺ Tumor-Initiating Cells
Researchers demonstrated that a subset of primary mantle cell lymphoma (MCL) cells co-cultured with either primary human mesenchymal stromal cells or murine MS-5 cells form in cobblestone-areas consisting of cells with a primitive immunophenotype containing the chromosomal translocation t (11;14)(q13;q32) characteristic of MCL. [PLoS One] Full Article

Design and In Vitro Evaluation of Layer by Layer siRNA Nanovectors Targeting Breast Tumor Initiating Cells
The stability, cell uptake, and release profile for small interfering RNA (siRNA) nanovectors (SNVs) were examined. In addition, SNVs reduced tumor initiating cell-related STAT3 expression levels, CD44⁺/CD24⁻/EpCAM⁺ surface marker levels and the number of mammospheres formed compared to the standard transfection agent. [PLoS One] Full Article

miR-612 Suppresses the Stemness of Liver Cancer via Wnt/β-Catenin Signaling
Researchers revealed that microRNA-612 (miR-612) is able to suppress the stemness of hepatocellular carcinoma by reducing the number and size of tumorspheres as well as clone formation in soft agar, and to relieve drug resistance to cisplatin and 5-fluorouracil. [Biochem Biophys Res Commun] Abstract

Cancer Stem Cells and Tumor Metastasis
The authors summarize current studies of cancer stem cells (CSCs) and tumor metastasis at the cellular level, with the goal of bringing new insights into understanding the role of CSCs in tumor metastasis. [Int J Oncol] Abstract | Download Full Article

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

Bezos Family Donates $20 Million to Fred Hutch to Develop Therapies that ‘Melt’ Cancer
Fred Hutchinson Cancer Research Center scientists striving for new cancer cures – and the patients who stand to benefit from them – got an enormous boost when the Bezos family committed $20 million to support the development of novel cancer immunotherapies. It is the largest single contribution in Fred Hutch’s history. [Fred Hutchinson Cancer Research Center] Press Release

Stand Up To Cancer Research Funding Opportunities
The American Association for Cancer Research (AACR), on behalf of Stand Up To Cancer (SU2C) and Cancer Research UK, is accepting applications for SU2C-Cancer Research UK Translational Research Fellowships that will offer up to $315,000 each in research funding. [The American Association for Cancer Research]
Press Release

New wallchart from our sponsor:
Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration). Request your free copy.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the cancer stem cell community.

Postdoctoral Research Associate – Extracellular Microenvironment in Cancer (Institute of Translational Medicine, University of Liverpool)

MSc & PhD Positions – Cell Biology, Neurobiology, Neuroimmunology, Cancer Biology, Computational Biology (Hanyang University)

Postdoctoral Fellowships – Cancer Research (German Cancer Research Center [DKFZ])

Faculty Positions – Cancer Research (Stephenson Cancer Center at the University of Oklahoma)

Postdoctoral Position – Cancer Biology (IRCAN)

Postdoctoral Position – Stem Cells and Cancer (Brigham & Women’s Hospital – Harvard Medical School)

Postdoctoral Fellow – Hematopoietic Stem Cell and Leukemia Research (City of Hope)

Tenure-Track Faculty Position – Cancer Biology and Evolution (Moffitt Cancer Center)

Postdoctoral Position – Glioblastoma, Oncolytic Virus and Cell Signaling (Ohio State University)

Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.